BioPharma Resources

Drug Trial Radar · NCT07488676

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

A Phase 1b/2 Open-label Study to Assess the Safety and Efficacy of ASP546C in Participants With CLDN18.2-expressing Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma, Pancreatic Adenocarcinoma or Other Solid Tumor Types

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

May 4, 2026

Primary completion

Jul 31, 2029

Study completion Jul 31, 2029

Sponsor

Lead sponsor
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
Sponsor type
Industry
First posted
Mar 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the food pipe (esophagus) joins the stomach. This study is in 2 parts. In both parts of the study, ASP546C will be given once in 3-week cycles. It will be given slowly through a tube into a vein. This is called an infusion. In Part 1, people with gastric cancer or GEJ cancer can take part. They will receive an infusion of either a higher dose or a lower dose of ASP546C. In Part 2, people with pancreatic cancer or who have one of the other solid tumors can take part. Part 2 doesn't include people with gastric cancer or GEJ cancer. All people in this part of the study will receive an infusion of the higher dose of ASP546C. People will visit the clinic on certain days to receive ASP546C and have health checks. The number of visits and checks done during the study will depend on the health of each person and whether they are still receiving infusions of ASP546C.

Conditions

  • Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
  • Pancreatic Adenocarcinoma

Interventions

  • ASP546CDrug

    Intravenous administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Objective Response Rate (ORR) per Investigator-assessed per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Time frame: Up to 36 Months
  2. Part 1: Pharmacokinetics (PK) of ASP546C Antibody-drug Conjugate (ADC): Serum Concentrations of Antibody-drug ConjugateTime frame: Up to 39 Months
  3. Part 1: PK of ASP546C ADC: Maximum Concentration (Cmax)Time frame: Up to 39 Months
  4. Part 1: PK of ASP546C ADC: Area Under the Serum Concentration-time Curve from Time Zero to 21Days (AUC0-21d)Time frame: Up to 39 Months
  5. Part 1: Number of participants with Adverse events (AEs)Time frame: Up to 39 Months
  6. Part 1: Number of Participants with Vital Sign Abnormalities and/or AEsTime frame: Up to 39 Months
  7. Part 1: Number of Participants with Laboratory Value Abnormalities and/or AEsTime frame: Up to 39 Months
  8. Part 1: Number of Participants at Each Grade of Eastern Cooperative Oncology Group (ECOG) Performance Status ScoresTime frame: Up to 39 Months

Locations

35 sites in 2 countries. Site status is shown where the registry gives one.

  • UAB Medicine - UAB Hospital

    Birmingham, Alabama · Recruiting

  • START Los Angeles

    Los Angeles, California · Recruiting

  • UC Irvine Health-Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • University of California San Francisco (UCSF) Medical Center

    San Francisco, California · Recruiting

  • Miami Cancer Institute

    Miami, Florida · Recruiting

  • Winship Cancer Institute at Emory University

    Atlanta, Georgia · Recruiting

  • Indiana University (IU) Health - Multi-D Oncology Clinic

    Indianapolis, Indiana · Recruiting

  • Barbara Ann Karmanos Cancer Center

    Detroit, Michigan · Recruiting

  • START Midwest

    Grand Rapids, Michigan · Recruiting

  • Health Partners Frauenshuh Cancer Center

    Saint Louis Park, Minnesota · Recruiting

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire · Recruiting

  • Memorial Sloan Kettering Basking Ridge

    Basking Ridge, New Jersey · Recruiting

  • Hackensack University Medical Center

    Hackensack, New Jersey · Recruiting

  • Memorial Sloan Kettering Cancer Center Monmouth

    Middletown, New Jersey · Recruiting

  • Memorial Sloan Kettering Bergen

    Montvale, New Jersey · Recruiting

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey · Recruiting

  • Memorial Sloan Kettering Commack

    Commack, New York · Recruiting

  • Memorial Sloan Kettering Westchester

    Harrison, New York · Recruiting

  • START New York

    Lake Success, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    Long Island City, New York · Recruiting

  • Memorial Sloan Kettering Nassau

    Uniondale, New York · Recruiting

  • Duke Cancer Center Durham

    Durham, North Carolina · Recruiting

  • Mercy Coletta Cancer Center

    Oklahoma City, Oklahoma · Recruiting

  • Next Oncology - Austin

    Austin, Texas · Recruiting

  • Next Oncology - Houston

    Houston, Texas · Recruiting

  • Next Oncology - Dallas

    Irving, Texas · Recruiting

  • START San Antonio (STSA)

    San Antonio, Texas · Recruiting

  • Huntsman Cancer Institute University of Utah

    Salt Lake City, Utah · Recruiting

  • START Mountain Region

    West Valley City, Utah · Recruiting

  • Inova Schar Cancer Institute Clinical Trials

    Fairfax, Virginia · Recruiting

  • Virginia Mason Medical Center

    Seattle, Washington · Recruiting

  • UW Health Carbone Cancer Center

    Madison, Wisconsin · Recruiting

  • National Cancer Center Hospital East

    Kashiwa-shi, Chiba, Japan · Recruiting

  • National Cancer Center Hospital

    Chuo-ku, Tokyo, Japan · Recruiting

  • The Cancer Institute Hospital of JFCR

    Koto-ku, Tokyo, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.